"Teva has been using the ProcessGene Suite for business process realization. ProcessGene's capability to encapsulate IT implementation artifacts and relate them to our business processes has been a central enabler for Teva's Oracle E-business suite global implementation."

Isaac Gilboa, CIO, Teva Pharmaceuticals Ltd.

**Customer Profile**

Teva Pharmaceutical Industries Ltd is the largest generic pharmaceutical company worldwide. Teva operates directly in over 40 countries.

**Business Situation**

Teva’s global ERP implementation is characterized by multiple deployments of the Oracle EBS solution in over 40 business units, geographical units and divisions. Company’s main implementation challenge has been to achieve global solution consistency by using a pre-configured and pre-tested business process baseline, yet enabling a relatively high operational flexibility to local business units – a “think global - act local” corporate strategy. Another challenge Teva faced has been the optimization of ERP knowledge transfer between the global baseline and local subsidiaries.

**ProcessGene’s Solution**

ProcessGene's Global Rollout solution enables multi-subsidiary organizations to distribute a unified process baseline, while allowing subsidiaries a controlled level of flexibility in determining local processes. The solution allows multi-subsidiary organizations to model their business processes, and enables users to view the interrelation of global and local practices. The "global baseline" is found at the top of a multi-organizational structure, and represents the organization's model outline. PG's Multi-Org application is unique in that it treats each subsidiary as a "Local" organization which is permitted certain unique practices not necessarily reflected in all subsidiaries.

**Benefits**

- Establishing a common organizational terminology and hierarchy for business processes.
- High level of correlation between user requirements and the actual ERP implementation.
- Clear visibility between the business processes and the supporting ERP system.
- Capability to re-use the business process baseline for ERP rollouts and upgrades.
- Retention of organizational knowledge at an easily accessible location, in a searchable and reportable format.
The ProcessGene™ Vision

ProcessGene™ is the industry leader in Business Process Realization

ProcessGene™ has been continuously innovating products and solutions in the field of Business Process Realization. We believe that business process innovation and excellence are crucial for the success of the business and for achieving strategic goals. Our solutions solve real customer pains, and show clear value generation results. ProcessGene™ provides the only end-to-end integrated solution for designing processes, supervising their realization, controlling changes and enforcing compliance.

Committed to Deliver the Industry’s Leading Business Process Realization System

Thanks to our unique expertise, we have been privileged to provide superior solutions to world leading organizations and be part of a thrilling global industry. Our executive team is committed to continue the translation of ProcessGene’s scientific innovation into outstanding product and business achievements.

Dr. Avi Wasser, Executive Director, ProcessGene™ Ltd.

ProcessGene Operations and R&D Center

Advanced Technologies Industrial Area (Matam)
PO 6607, Haifa 31066, Israel
Tel: +972 (4) 855 0258
Fax: +972 (4) 837 5532
Email: info@processgene.com

www.processgene.com

This report does not present a complete description of the company, nor does it contain all relevant information for the decision of a prospective investor or customer. To the extent that this report contains statements in relation to the future development or offering of the company, in particular the product and business development, such statements are based on individual determinations by the company which may prove to be correct or incorrect. The company shall not be liable for the correctness and completeness of the information, the conclusions and predictions in this report.